UBS Downgrades Salix Pharmaceuticals To Neutral

Analysts at UBS downgraded

from Buy to Neutral. The price target for Salix Pharmaceuticals has been raised from $144.00 to $158.00. Salix Pharmaceuticals shares have gained 43.94% over the past 52 weeks, while the S&P 500 index has surged 14.34% in the same period. Salix Pharmaceuticals' shares fell 0.10% to $155.60 in pre-market trading.